keyword
MENU ▼
Read by QxMD icon Read
search

Ebola vaccine

keyword
https://www.readbyqxmd.com/read/29163402/pharmacological-induction-of-heme-oxygenase-1-impairs-nuclear-accumulation-of-herpes-simplex-virus-capsids-upon-infection
#1
Francisco J Ibáñez, Mónica A Farías, Angello Retamal-Díaz, Janyra A Espinoza, Alexis M Kalergis, Pablo A González
Heme oxygenase-1 (HO-1) is an inducible enzyme that is expressed in response to physical and chemical stresses, such as ultraviolet radiation, hyperthermia, hypoxia, reactive oxygen species (ROS), as well as cytokines, among others. Its activity can be positively modulated by cobalt protoporphyrin (CoPP) and negatively by tin protoporphirin (SnPP). Once induced, HO-1 degrades iron-containing heme into ferrous iron (Fe(2+)), carbon monoxide (CO) and biliverdin. Importantly, numerous products of HO-1 are cytoprotective with anti-apoptotic, anti-oxidant, anti-inflammatory, and anti-cancer effects...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29161839/the-potential-impact-of-a-prophylactic-vaccine-for-ebola-in-sierra-leone
#2
Erin N Bodine, Connor Cook, Mikayla Shorten
The 2014 outbreak of Ebola virus disease (EVD) in West Africa was multinational and of an unprecedented scale primarily affecting the countries of Guinea, Liberia, and Sierra Leone. One of the qualities that makes EVD of high public concern is its potential for extremely high mortality rates (up to 90%). A prophylactic vaccine for ebolavirus (rVSV-ZEBOV) has been developed, and clinical trials show near-perfect efficacy. We have developed an ordinary differential equations model that simulates an EVD epidemic and takes into account (1) transmission through contact with infectious EVD individuals and deceased EVD bodies, (2) the heterogeneity of the risk of becoming infected with EVD, and (3) the increased survival rate of infected EVD patients due to greater access to trained healthcare providers...
April 1, 2018: Mathematical Biosciences and Engineering: MBE
https://www.readbyqxmd.com/read/29155670/lessons-learned-from-emergency-response-vaccination-efforts-for-cholera-typhoid-yellow-fever-and-ebola
#3
Jenny A Walldorf, Kashmira A Date, Nandini Sreenivasan, Jennifer B Harris, Terri B Hyde
Countries must be prepared to respond to public health threats associated with emergencies, such as natural disasters, sociopolitical conflicts, or uncontrolled disease outbreaks. Rapid vaccination of populations vulnerable to epidemic-prone vaccine-preventable diseases is a major component of emergency response. Emergency vaccination planning presents challenges, including how to predict resource needs, expand vaccine availability during global shortages, and address regulatory barriers to deliver new products...
December 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/29153266/ebola-virus-disease-an-update-on-post-exposure-prophylaxis
#4
REVIEW
William A Fischer, Pauline Vetter, Daniel G Bausch, Timothy Burgess, Richard T Davey, Robert Fowler, Frederick G Hayden, Peter B Jahrling, Andre C Kalil, Douglas L Mayers, Aneesh K Mehta, Timothy M Uyeki, Michael Jacobs
The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016 resulted in intense efforts to evaluate the efficacy of several specific countermeasures developed through years of preclinical work, including the first clinical trials for therapeutics and vaccines. In this Review, we discuss how the experience and data generated from that outbreak have helped to advance the understanding of the use of these countermeasures for post-exposure prophylaxis against Ebola virus infection. In future outbreaks, post-exposure prophylaxis could play an important part in reducing community transmission of Ebola virus by providing more immediate protection than does immunisation as well as providing additional protection for health-care workers who are inadvertently exposed over the course of their work...
November 15, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29148858/from-bench-to-almost-bedside-the-long-road-to-a-licensed-ebola-virus-vaccine
#5
Gary Wong, Emelissa J Mendoza, Francis A Plummer, George F Gao, Gary P Kobinger, Xiangguo Qiu
The Ebola virus (EBOV) disease epidemic during 2014-16 in West Africa has accelerated the clinical development of several vaccine candidates that have demonstrated efficacy in the gold standard nonhuman primate (NHP) model, namely cynomolgus macaques. Areas covered: This review discusses the pre-clinical research and if available, clinical evaluation of the currently available EBOV vaccine candidates, while emphasizing the translatability of pre-clinical data generated in the NHP model to clinical data in humans...
November 17, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29142131/single-dose-trivalent-vesiculovax-vaccine-protects-macaques-from-lethal-ebolavirus-and-marburgvirus-challenge
#6
Demetrius Matassov, Chad E Mire, Theresa Latham, Joan B Geisbert, Rong Xu, Ayuko Ota-Setlik, Krystle N Agans, Dean J Kobs, Morgan Q S Wendling, Amanda Burnaugh, Thomas L Rudge, Carol L Sabourin, Michael A Egan, David K Clarke, Thomas W Geisbert, John H Eldridge
Previous studies demonstrated that a single intramuscular (IM) dose of an attenuated vesicular stomatitis virus vector (Vesiculovax™, rVSV-N4CT1) expressing the glycoprotein (GP) from the Mayinga strain of Zaire ebolavirus (EBOV) protected nonhuman primates (NHP) from lethal challenge with EBOV Kikwit and Makona strains. Here we studied the immunogenicity of an expanded range of attenuated rVSV vectors expressing filovirus GP in mice. Based on data from those studies an optimal attenuated tri-valent rVSV vector formulation was identified which included rVSV vectors expressing EBOV, Sudan ebolavirus (SUDV) or Angola strain of Marburg marburgvirus (MARV) GPs...
November 15, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29135337/dna-vaccines-elicit-durable-protective-immunity-against-individual-or-simultaneous-infections-with-lassa-and-ebola-viruses-in-guinea-pigs
#7
Kathleen A Cashman, Eric R Wilkinson, Suzanne E Wollen, Joshua D Shamblin, Justine M Zelko, Jeremy J Bearss, Xiankun Zeng, Kate E Broderick, Connie S Schmaljohn
We previously developed optimized DNA vaccines against both Lassa fever and Ebola hemorrhagic fever viruses and demonstrated that they were protective individually in guinea pig and nonhuman primate models. In this study, we vaccinated groups of strain 13 guinea pigs two times, four weeks apart with 50 µg of each DNA vaccine or a mock vaccine at discrete sites by intradermal electroporation. Five weeks following the second vaccinations, guinea pigs were exposed to lethal doses of Lassa virus, Ebola virus, or a combination of both viruses simultaneously...
November 14, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29128378/ebola-virus-disease-report-from-the-task-force-on-tropical-diseases-by-the-world-federation-of-societies-of-intensive-and-critical-care-medicine
#8
REVIEW
Guy A Richards, Tim Baker, Pravin Amin
Ebola virus is a filovirus that can cause fatal hemorrhagic fever (HF) and five distinct species exist that vary in terms of geographical distribution and virulence. Once the more virulent forms enter the human population, transmission occurs primarily through direct contact with infected body fluids and may result in significant outbreaks. The devastating has been the recent West African outbreak. Clinically, signs and symptoms are similar to those of the other VHFs [4]. The incubation period is 2-21days, followed by fever, headache, myalgia, diarrhoea, vomiting and dehydration; thereafter, there may be recovery or deterioration with collapse, neurological manifestations and bleeding, that can lead to a fatal outcome...
November 3, 2017: Journal of Critical Care
https://www.readbyqxmd.com/read/29122384/strengthening-global-vaccine-access-for-adolescents-and-adults
#9
REVIEW
Angeline Nanni, Stefanie Meredith, Stephanie Gati, Karin Holm, Tom Harmon, Ann Ginsberg
Global immunization efforts to date have heavily focused on infants and children, with noted success on public health. Healthy adolescents and adults contribute to the economic growth and development of countries but efforts to ensure vaccine coverage for these groups receive inadequate global attention and resources. Emerging epidemics for a number of infectious diseases including Ebola, Zika, dengue, malaria and the continuing epidemics of tuberculosis and several sexually transmitted infections, including HIV, HPV and Hepatitis B, have high incidence and prevalence in adolescents and adults...
November 6, 2017: Vaccine
https://www.readbyqxmd.com/read/29109373/development-of-a-lethal-intranasal-exposure-model-of-ebola-virus-in-the-cynomolgus-macaque
#10
Kendra J Alfson, Laura E Avena, Gabriella Worwa, Ricardo Carrion, Anthony Griffiths
Ebola virus (EBOV) is a filovirus that can cause Ebola virus disease (EVD). No approved vaccines or therapies exist for filovirus infections, despite an urgent need. The development and testing of effective countermeasures against EBOV requires use of animal models and a thorough understanding of how the model aligns with EVD in humans. The majority of published studies report outcomes of parenteral exposures for emulating needle stick transmission. However, based on data from EVD outbreaks, close contact exposures to infected bodily fluid seems to be one of the primary routes of EBOV transmission...
October 29, 2017: Viruses
https://www.readbyqxmd.com/read/29104771/virus-vectored-ebola-vaccines
#11
I V Dolzhikova, E A Tokarskaya, A S Dzharullaeva, A I Tukhvatulin, D V Shcheblyakov, O L Voronina, S I Syromyatnikova, S V Borisevich, V B Pantyukhov, V F Babira, L V Kolobukhina, B S Naroditsky, D Y Logunov, A L Gintsburg
The Ebola virus disease (EVD) is one of the most dangerous infections affecting humans and animals. The first EVD outbreaks occurred in 1976 in Sudan and Zaire. Since then, more than 20 outbreaks have occurred; the largest of which (2014-2016) evolved into an epidemic in West Africa and claimed the lives of more than 11,000 people. Although vaccination is the most effective way to prevent epidemics, there was no licensed vaccine for EVD at the beginning of the latest outbreak. The development of the first vaccines for EVD started in 1980 and has come a long technological way, from inactivated to genetically engineered vaccines based on recombinant viral vectors...
July 2017: Acta Naturae
https://www.readbyqxmd.com/read/29083948/chimpanzee-adenoviral-vectors-as-vaccines-for-outbreak-pathogens
#12
Katie Ewer, Sarah Sebastian, Alexandra J Spencer, Sarah Gilbert, Adrian V S Hill, Teresa Lambe
The 2014-15 Ebola outbreak in West Africa highlighted the potential for large disease outbreaks caused by emerging pathogens and has generated considerable focus on preparedness for future epidemics. Here we discuss drivers, strategies and practical considerations for developing vaccines against outbreak pathogens. Chimpanzee adenoviral (ChAd) vectors have been developed as vaccine candidates for multiple infectious diseases and prostate cancer. ChAd vectors are safe and induce antigen-specific cellular and humoral immunity in all age groups, as well as circumventing the problem of pre-existing immunity encountered with human Ad vectors...
October 30, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29074200/data-management-of-clinical-trials-during-an-outbreak-of-ebola-virus-disease
#13
Stefanie Hossmann, Alan G Haynes, Adrian Spoerri, Ibrahima Dina Diatta, Barry Aboubacar, Matthias Egger, Felix Rintelen, Sven Trelle
INTRODUCTION: Clinical trial data management (DM) conducted during outbreaks like that of Ebola virus disease (EVD) in West Africa, 2014-2016, has to adapt to specific, unique circumstances. CTU Bern was asked to set up a safe data capture/management system that could be launched within a few weeks and cover two different vaccine trials. This article describes some of the challenges we faced and our solutions during the two different trials. METHODS: Setting up a DM system was split into four phases/tasks: (1) quick set-up of the (electronic) data capture system (EDC) and mobile infrastructure in Bern, (2) moving the EDC and infrastructure to Conakry, Guinea and implementation of a local data management centre (DMC), (3) running the DMC, and (4) data cleaning...
October 23, 2017: Vaccine
https://www.readbyqxmd.com/read/29073992/ebola-virus-epidemic-in-west-africa-global-health-economic-challenges-lessons-learned-and-policy-recommendations
#14
Mahmoud Elmahdawy, Gihan H Elsisi, Joao Carapinha, Mohamed Lamorde, Abdulrazaq Habib, Peter Agyie-Baffour, Redouane Soualmi, Samah Ragab, Anthony W Udezi, Cyril Usifoh, Stella Usifoh
The Ebola virus has spread across several Western Africa countries, adding a significant financial burden to their health systems and economies. In this article the experience with Ebola is reviewed, and economic challenges and policy recommendations are discussed to help curb the impact of other diseases in the future. The West African Ebola virus disease epidemic started in resource-constrained settings and caused thousands of fatalities during the last epidemic. Nevertheless, given population mobility, international travel, and an increasingly globalized economy, it has the potential to re-occur and evolve into a global pandemic...
September 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/29058516/clinician-initiated-research-on-treating-the-host-response-to-pandemic-influenza
#15
David S Fedson
To prepare for the next influenza pandemic and other emerging virus diseases, scientists and health officials are focused on developing new vaccines and treatments that target these viruses. Ideally, these interventions could be highly effective, but for many practical reasons these "top down" efforts are unlikely to provide clinicians with what they will need to manage their patients. As a "bottom up" alternative, combinations of generic drugs like statins and angiotensin receptor blockers (ARBs) might be used to treat the host response to infection...
October 23, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29033035/an-effective-and-safe-vaccine-will-not-be-enough-to-prepare-us-for-the-next-ebola-outbreak
#16
John S Schieffelin
No abstract text is available yet for this article.
October 9, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29033032/ring-vaccination-with-rvsv-zebov-under-expanded-access-in-response-to-an-outbreak-of-ebola-virus-disease-in-guinea-2016-an-operational-and-vaccine-safety-report
#17
Pierre-Stéphane Gsell, Anton Camacho, Adam J Kucharski, Conall H Watson, Aminata Bagayoko, Séverine Danmadji Nadlaou, Natalie E Dean, Abdourahamane Diallo, Abdourahmane Diallo, Djidonou A Honora, Moussa Doumbia, Godwin Enwere, Elizabeth S Higgs, Thomas Mauget, Diakite Mory, Ximena Riveros, Fofana Thierno Oumar, Mosoka Fallah, Alhassane Toure, Andrea S Vicari, Ira M Longini, W J Edmunds, Ana Maria Henao-Restrepo, Marie Paule Kieny, Sakoba Kéïta
BACKGROUND: In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting. METHODS: Approval for expanded access and compassionate use was rapidly sought and obtained from relevant authorities...
October 9, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29032747/development-of-potential-small-molecule-therapeutics-for-treatment-of-ebola-virus
#18
Adam Michael Schafer, Han Cheng, Charles Lee, Ruikun Du, Julianna Han, Jasmine Perez, Norton Peet, Balaji Manicassamy, Lijun Rong
Ebola virus has caused 26 outbreaks in 10 different countries since its identification in 1976, making it one of the deadliest emerging viral pathogens. The most recent outbreak in West Africa from 2014-16 was the deadliest yet and culminated in 11,310 deaths out of 28,616 confirmed cases. Currently there are no FDA-approved therapeutics or vaccines to treat Ebola virus infections. The slow development of effective vaccines combined with the severity of past outbreaks emphasizes the need to accelerate research into understanding the virus lifecycle and the development of therapeutics for post exposure treatment...
October 10, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29020589/phase-2-placebo-controlled-trial-of-two-vaccines-to-prevent-ebola-in-liberia
#19
RANDOMIZED CONTROLLED TRIAL
Stephen B Kennedy, Fatorma Bolay, Mark Kieh, Greg Grandits, Moses Badio, Ripley Ballou, Risa Eckes, Mark Feinberg, Dean Follmann, Birgit Grund, Swati Gupta, Lisa Hensley, Elizabeth Higgs, Krisztina Janosko, Melvin Johnson, Francis Kateh, James Logue, Jonathan Marchand, Thomas Monath, Martha Nason, Tolbert Nyenswah, François Roman, Eric Stavale, Julian Wolfson, James D Neaton, H Clifford Lane
BACKGROUND: The safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidence of EVD was peaking in Liberia. METHODS: We initiated a randomized, placebo-controlled, phase 3 trial of the chimpanzee adenovirus 3 vaccine (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSV∆G-ZEBOV-GP) in Liberia. A phase 2 subtrial was embedded to evaluate safety and immunogenicity. Because the incidence of EVD declined in Liberia, the phase 2 component was expanded and the phase 3 component was eliminated...
October 12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28986847/future-approaches-to-dna-vaccination-against-hemorrhagic-fever-viruses
#20
John J Suschak, Connie S Schmaljohn
To date, there is no protective vaccine for Ebola virus infection. Safety concerns have prevented the use of live-attenuated vaccines, and forced researchers to examine new vaccine formulations. DNA vaccination is an attractive method for inducing protective immunity to a variety of pathogens, but the low immunogenicity seen in larger animals and humans has hindered its usage. Various approaches have been used to improve the immunogenicity of DNA vaccines, but the most successful, and widespread, is electroporation...
2018: Methods in Molecular Biology
keyword
keyword
41124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"